INTACt
ImmuNogenomics TArgeting Cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0INTACt project word cloud
Explore the words cloud of the INTACt project. It provides you a very rough idea of what is the project "INTACt" about.
Project "INTACt" data sheet
The following table provides information about the project.
| Coordinator |
WEIZMANN INSTITUTE OF SCIENCE
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2016-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-06-01 to 2018-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | WEIZMANN INSTITUTE OF SCIENCE | IL (REHOVOT) | coordinator | 150˙000.00 |
Map
Project objective
Melanoma is the most aggressive, treatment-resistant and lethal type of skin cancer. Its increasing incidence worldwide emphasizes the need for new treatment strategies. Major recent breakthroughs in melanoma therapy have highlighted the role of immune T cell-mediated responses against tumor cells, showing that immune-system recognition of neo-antigens on cancer cells serves as a distinctive immunological signature. However, current strategies to identify neo-antigens are biased, costly and time-consuming. Directly addressing this major therapeutic limitation, this PoC project is aimed at commercializing an innovative tool, called INTACt, for designing highly personalized therapies for melanoma patients, ones that efficiently target the composition of patient-specific neo-antigens that arise as a consequence of mutations in a patient’s melanoma genome. INTACt is designed to identify neo-antigens in a high-throughput, systematic and cost-effective manner in cell lines, fresh tumors, patient-derived xenografts and plasma. INTACt will further identify the patient neo-antigen-reactive T cells to then be returned to the patient, using neo-antigen-specific T cells or RNA vaccines. Such personalized targeting of the patient’s melanoma genetic landscape is key to a significantly improved mortality. Unlike existing therapeutic strategies, INTACt may be considered the ultimate personalized immune therapy for the treatment of melanoma patients to be expended to other cancer types. This patient-specific tool will significantly lower patients’ economic and psychological burden caused by unnecessary chemotherapy and targeted therapy. INTACt also holds the promise of realizing value from enormous past investments in drug candidates that were eliminated due to person-specific toxicities or lack of efficacy as these can be combined with the neo-antigen-based immunotherapy. INTACt will thus enable the creation of new business models for the highly pressured pharmaceutical industry.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Michal Alon, Rand Arafeh, Joo Sang Lee, Sanna Madan, Shelly Kalaora, Adi Nagler, Tereza Abgarian, Polina Greenberg, Eytan Ruppin, Yardena Samuels CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.25805 |
Oncotarget 9/58 | 2019-06-05 |
| 2018 |
Michal Alon, Rafi Emmanuel, Nouar Qutob, Anna Bakhman, Victoria Peshti, Alexandra Brodezki, David Bassan, Mickey Kosloff, Yardena Samuels Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma published pages: 641-648, ISSN: 1755-1471, DOI: 10.1111/pcmr.12705 |
Pigment Cell & Melanoma Research 31/5 | 2019-06-05 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTACT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INTACT" are provided by the European Opendata Portal: CORDIS opendata.